DAXOR CORP 10-Q Summary: Quarter Ended March 31, 2000
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended March 31, 2000. DAXOR Corporation operates in two primary segments: laboratory services (semen and blood banking) and the development/marketing of the BVA-100 Blood Volume Analyzer. The company also maintains a significant portfolio of marketable securities, primarily utility stocks, classified as "Available-For-Sale."
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 |
|---|---|---|
| Total Revenues | $717,736 | $990,329 |
| Operating Revenues | $211,559 | $119,327 |
| Net Income | $93,993 | $313,186 |
| Diluted EPS | $0.02 | $0.07 |
| Cash and Equivalents | $98,298 | $110,237 |
| Marketable Securities (Fair Value) | $35,123,978 | $34,867,286 |
| Total Assets | $35,990,263 | $35,846,065 |
| Total Liabilities | $6,700,742 | $6,566,496 |
| Shareholders' Equity | $29,289,521 | $29,279,569 |
| Loans Payable | $2,558,160 | $2,443,794 |
Margin Analysis: Operating expenses ($577,301) exceeded operating revenues ($211,559) for the quarter. Profitability was driven by investment income (dividends and capital gains) rather than core operations.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 27.5% year-over-year, primarily due to a sharp drop in gains on the sale of securities ($8,242 in 2000 vs. $403,637 in 1999).
- Operating Growth: Operating revenues increased 77.3% to $211,559, marking the first quarter with income from BVA-100 Blood Volume Analyzer sales.
- Net Income Drop: Net income fell 70% to $93,993, reflecting the absence of significant capital gains realized in the prior year.
- Debt Increase: Loans payable increased by approximately $114,000, driven by higher margin debt used to purchase investments.
Outlook, Risks, and Management Commentary
Outlook: Management anticipates that sales of the BVA-100 equipment and kits will become the major source of income. The company is currently initiating distribution networks but has not yet received income from sales by non-company personnel. They are evaluating options for a nationwide sales force versus independent dealer networks and are considering acquiring additional capital to accelerate marketing.
Capital Strategy: The company utilizes an "instrument loaner reagent plan" which requires the use of reserves and results in a slower return on capital expenditure compared to direct sales or leases, though it may offer higher ultimate returns due to reagent costs.
Risks and Contingencies:
- Liquidity: While the company states it has adequate resources for current marketing levels, cash on hand is low ($98,298) relative to total assets, which are heavily concentrated in marketable securities.
- Debt Security: Loans totaling $2.56 million are secured by the company's marketable securities. A significant decline in the portfolio value could trigger margin calls.
- Market Adoption: The success of the BVA-100 is unproven at scale; experience to date is too limited to determine if sales or loaner plans will predominate.
Investor Verification Checklist
- Verify the sustainability of operating revenue growth from the BVA-100 in subsequent quarters.
- Confirm the stability of the marketable securities portfolio given the $2.56 million in secured debt.
- Assess the timeline for establishing independent distribution networks to reduce reliance on internal sales.
- Monitor cash burn rates relative to the low cash balance ($98k) and the capital requirements for national marketing expansion.